SCHEMBL6318150

SCHEMBL6318150

Cc1ccc(NC(=O)c2c(-c3ccc4ccccc4n3)noc2N)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 8/20 0.49
CA2 P00918 8/20 0.49
CA4 P22748 8/20 0.49
CA7 P43166 8/20 0.49
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
CYP3A4 P08684 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 2/20 0.43
USP2 O75604 1/20 0.43
PDGFRB P09619 1/20 0.42
FLT3 P36888 1/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316271 0.82 NPC1 (0.49) CA1CA2CA4CA7CYP1A2
SCHEMBL6316431 0.81 CA1 (0.52) CA1CA2CA4CA7CYP1A2
SCHEMBL6316714 0.80 RAB9A (0.45) CA1CA2CA4CA7CYP1A2
SCHEMBL6321873 0.80 RAB9A (0.53) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL6616343 0.80 SMO (0.40) CA1CA2CA4CA7CYP1A2
SCHEMBL6316105 0.79 NPC1 (0.46) CA1CA2CA4CA7CYP1A2
SCHEMBL6317601 0.79 NPC1 (0.42) CYP1A2CYP2C9NPC1RAB9AGAA
SCHEMBL6317061 0.77 ALDH1A1 (0.44) CA1CA2CA4CA7NPC1
SCHEMBL6315713 0.75 KDM4E (0.62) CA1CA2CA4CA7CYP1A2
SCHEMBL6316560 0.75 SMN1; SMN2 (0.59) CA1CA2CA4CA7CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 CA1 2406/4885CA2 2764/4885CA4 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.